Want to see SIGA full AI Analyst Report?
SIGA Stock Chart & Stats
$6.77
-$0.07(-1.11%)
At close: 4:00 PM EST
$6.77
-$0.07(-1.11%)
Day’s Range― - ―
52-Week Range$3.41 - $9.62
Previous CloseN/A
Volume59.56K
Average Volume (3M)461.52K
Market Cap
$246.73M
Enterprise Value$164.21M
Total Cash (Recent Filing)$145.56M
Total Debt (Recent Filing)$638.23K
Price to Earnings (P/E)12.0
Beta1.47
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding71,724,100
10 Day Avg. Volume376,632
30 Day Avg. Volume461,516
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio10.15
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda5.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$66.31M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & No DebtA cash balance ~ $146M and effectively zero debt provide multi‑quarter runway and financial optionality. This durable strength supports R&D, regulatory activities, manufacturing tech transfer, and shareholder returns without near‑term refinancing risk, improving strategic flexibility.
Positive Operating And Free Cash FlowTTM positive operating and free cash flow indicate core commercial operations generate cash despite earnings volatility. Sustained cash generation funds ongoing pediatric and PEP development, supports special dividends and partnership investments, enhancing long‑term self‑funding capacity.
Commercial & Pipeline DiversificationRecent international orders, an exclusive Hikma MENA distribution agreement, and progressing pediatric/PEP programs together broaden addressable markets and reduce sole reliance on U.S. SNS buys. These structural additions can convert episodic procurements into more diversified, multi‑regional revenue streams over time.
Bears Say
Steep Revenue Decline & Lumpy DemandSharp recent revenue declines and an inherently episodic procurement model make revenue timing and forecasting unreliable. Dependence on intermittent government stockpiles and outbreak responses increases earnings volatility and limits predictability of sustained commercial revenue over the next several quarters.
Large TTM Net Loss And Reporting DistortionsAn outsized TTM net loss and unusual equity movements undermine confidence in near‑term profitability metrics. Even with positive cash flow, such accounting losses complicate assessment of operating sustainability, may mask one‑time/nonoperating items, and increase earnings unpredictability for investors.
Regulatory & Contract HeadwindsA CHMP recommendation to withdraw an EU indication reduces potential European market access and adds remediation burden. Coupled with delayed U.S. government contracting, these structural headwinds weaken the primary demand channels for TPOXX and heighten near‑to‑mid term revenue risk.
SIGA Technologies News
SIGA FAQ
What was SIGA Technologies Inc’s price range in the past 12 months?
SIGA Technologies Inc lowest stock price was $3.41 and its highest was $9.62 in the past 12 months.
What is SIGA Technologies Inc’s market cap?
SIGA Technologies Inc’s market cap is $246.73M.
When is SIGA Technologies Inc’s upcoming earnings report date?
SIGA Technologies Inc’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were SIGA Technologies Inc’s earnings last quarter?
SIGA Technologies Inc released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is SIGA Technologies Inc overvalued?
According to Wall Street analysts SIGA Technologies Inc’s price is currently Overvalued.
Does SIGA Technologies Inc pay dividends?
SIGA Technologies Inc pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on SIGA Technologies Inc dividends here
What is SIGA Technologies Inc’s EPS estimate?
SIGA Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SIGA Technologies Inc have?
SIGA Technologies Inc has 71,724,100 shares outstanding.
What happened to SIGA Technologies Inc’s price movement after its last earnings report?
SIGA Technologies Inc reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.48%.
Which hedge fund is a major shareholder of SIGA Technologies Inc?
Currently, no hedge funds are holding shares in SIGA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SIGA Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 132.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.20%
Trailing 12-Months
Company Description
SIGA Technologies Inc
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
SIGA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.View all SIGA earnings summariesTechnical Analysis
Ownership Overview
1.75% Insiders
12.31% Mutual Funds
0.04% Other Institutional Investors
75.07% Public Companies and
Individual Investors